Shionogi & Co Ltd Executive and Leadership Team

Takeshi Kasuya, the Chief Executive Officer at Shionogi & Co Ltd, directs the overarching corporate strategy and long-term vision for the organization. This leadership role involves aligning research initiatives with global market demands to address critical infectious disease challenges. By fostering strategic collaborations with international biotech partners and academic institutions, the Chief Executive Officer ensures the rapid advancement of the pharmaceutical pipeline. Takeshi Kasuya maintains rigorous oversight of organizational performance, driving efficiency across all departments to support the development of novel antibiotics and antiviral treatments. Through constant engagement with the Board, the Chief Executive Officer secures the necessary resources for scaling operations across diverse international markets. This executive leadership maintains a focus on sustainable growth while prioritizing the delivery of life-saving medications to patients worldwide. Ultimately, Kasuya drives the company toward achieving its mission of improving global health outcomes through scientific innovation and operational excellence.

Isao Teshirogi, the Representative Director, President & Chief Executive Officer at Shionogi & Co Ltd, manages the primary governance and executive execution of the company. This role involves architecting the strategic framework for pharmaceutical development, specifically targeting emerging viral threats and infectious diseases. By overseeing the integration of in-house research with external government and industry partnerships, the Representative Director, President & Chief Executive Officer accelerates the path from discovery to patient access. Isao Teshirogi drives the corporate culture toward precision and urgency, ensuring that all scientific programs meet the highest standards of efficacy. This leadership position requires constant coordination with global stakeholders to expand the reach of therapeutic solutions. Through meticulous management of the company's portfolio, the Representative Director, President & Chief Executive Officer secures a competitive position in the global pharmaceutical landscape. Teshirogi ultimately ensures that the organization remains at the forefront of medical innovation.

Art Deas, the Chief Operating Officer at Shionogi & Co Ltd, directs the internal scaling and operational infrastructure required to support global pharmaceutical manufacturing. This role involves optimizing supply chain logistics and ensuring that production facilities maintain compliance with international health standards. By streamlining cross-functional workflows, the Chief Operating Officer enables the seamless transition of research projects into large-scale commercial production. Art Deas manages the operational budget and resource allocation, ensuring that the company maintains the agility needed to respond to emerging health crises. This leadership role requires close collaboration with the executive team to align operational capacity with the strategic goals of the organization. Through the implementation of advanced manufacturing technologies, the Chief Operating Officer enhances the efficiency of drug delivery systems. Deas ensures that the company maintains a robust operational presence across key global regions, supporting the consistent availability of essential medications for patients in need.

Tsutae (Den) Nagata, the Chief Medical Officer at Shionogi & Co Ltd, directs the clinical development and medical affairs strategy for the entire pharmaceutical portfolio. This role involves overseeing the design and execution of clinical trials for novel antibiotics, HIV treatments, and influenza therapies. By ensuring that all scientific programs adhere to rigorous safety and efficacy protocols, the Chief Medical Officer facilitates the successful regulatory approval of new medications. Tsutae (Den) Nagata manages the medical science liaison teams, providing critical data to healthcare providers and academic institutions to support the adoption of innovative therapies. This leadership position requires constant interaction with global health authorities to navigate complex regulatory environments. Through the application of deep medical expertise, the Chief Medical Officer shapes the clinical narrative and therapeutic impact of the company's research. Nagata ultimately ensures that all medical initiatives directly contribute to improving patient lives through evidence-based medicine.